Kingsley L. Taft
Corporate Officer/Principal at Goodwin Procter LLP
Kingsley L. Taft active positions
| Companies | Position | Start | End |
|---|---|---|---|
Goodwin Procter LLP
 Goodwin Procter LLP Investment ManagersFinance Goodwin Procter LLP is a law firm which provides advice to companies in public and private enterprises. It provides services to financial, life sciences, private equity, real estate, and technolgy industries. The company was founded in 1912 and is headquartered in Boston, MA. | Corporate Officer/Principal | 31/05/2004 | - |
Career history of Kingsley L. Taft
Former positions of Kingsley L. Taft
| Companies | Position | Start | End |
|---|---|---|---|
Semma Therapeutics, Inc.
 Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | Corporate Secretary | - | - |
Statistics
International
| United States | 3 |
Operational
| Corporate Officer/Principal | 1 |
| Corporate Secretary | 1 |
Sectoral
| Finance | 2 |
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
Goodwin Procter LLP
Goodwin Procter LLP Investment ManagersFinance Goodwin Procter LLP is a law firm which provides advice to companies in public and private enterprises. It provides services to financial, life sciences, private equity, real estate, and technolgy industries. The company was founded in 1912 and is headquartered in Boston, MA. | Finance |
Semma Therapeutics, Inc.
Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Kingsley L. Taft
- Experience
